SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

Technology That Boldly Redefines
the EP Lab

Bold Solutions to Challenge AFib

Bold Solutions to Challenge AFib
Innovate

Reinventing the Technology You Rely On Everyday

A solutions-based approach to innovation, Abbott’s EP portfolio is designed to improve your procedure experience. Our approach to technology helps physicians deliver better outcomes faster by focusing on three key factors:

Download Solution Portfolio

Efficiency

Get In and Out of Your Lab in Less Time

Bold technology lets you treat more patients in less time. With Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, procedure times are reduced by an average of 34 minutes versus CMCs1

 

alarm clock icon

Know You are Doing it Right the First Time

Efficiency is not just about reduction in procedure times. Bold technology should also promise less repeat procedures and reduced all-cause events. Advisor™ HD Grid Mapping Catheter has shown a 14% reduction in redo procedures compared to CMCs2 and TactiCath™ Ablation Catheter, SE results in decreased healthcare utilization by reducing all-cause annual event rates by more than 53%3

 

Reduction
REDUCED AFIB
FLUORO TIME3
Reduced Afib Fluoro Time
REDUCED RADIATION
EXPOSURE IN THE LAB4
Reduced Radiation Exposure in the Lab

Accuracy

Boldness in treating AFib requires technology that never sacrifices accuracy or efficiency. Abbott’s EP portfolio delivers both.

 

Illustration of a human heart
Heart monitor screen
Redefine signal quality when paired with a best-in-class high density mapping catheter that improves the signal to noise ratio with a noise floor of 0.01 mV6

Cleaner Maps with Automatic Removal of Outliers

EnSite™ X Software Verson 2 provides a more accurate mapping experience by automatically removing outliers.

Accuracy

 

Accurate contact force matters during your ablation procedures. TactiCath™ Contact Force Catheter, Sensor Enabled™ has shown 6x greater accuracy in lateral orientation for contact force ablation than the competition.6,7

Ablation graph

Patient Outcomes

Your end goal is for your patients to be well. Abbott’s focus on creating technologies that are efficient and accurate gives you the tools you need to boldly redefine patient outcomes and change your patients’ lives. Bold solutions to challenge AFib is –

 

Freeing Your Patients From Atrial Arrhythmias

12-month freedom from atrial arrhythmias with Advisor HD Grid Mapping Catheter, Sensor Enabled1

grid percentages

Freedom of arrhythmia at 12 months with Agilis NxT Steerable Sheath9

Graph showing percentages of patients free of arrhythmia

 

Driving clinical success in Paroxysmal and Persistent AFib

  • Achieving an 82.2% clinical success rate for paroxysmal AFib at one year10
  • And a 90% symptomatic success rate at 15 months - using the TactiCath Ablation Catheter, Sensor Enabled10

% of patients reporting improved quality of life at 12 months following ablation11

Paroxysmal and Persistent percentages

Free Your Patients From the Use of OACS for Stroke Risk Reduction

Ischemic stoke rate reduced by 67% compared to predicted risk12

Graph showing reduction in Ischemic stroke rate

With the Amplatzer™ Amulet™ Left Atrial Appendage Occluder (LAAO) you do both – not only delivering a 67% lower stroke rate, but also allowing 8 out of 10 patients to be discharged without OACs.12 Amplatzer Amulet LAAO is the only FDA-approved LAAO that does not require use of OACs at discharge.

         ELEVATE

Clinical support that elevates your
practice to meet today's challenges

Learn More

 IMPACT

Partnerships that drive
impact for the EP community

Learn More
people icon

 

References

  1. Day, J. D., Crandall, B., Cutler, M., Osborn, J., Miller, J., Mallender, C., & Lakkireddy, D. (2020). High Power Ultra Short Duration Ablation with HD Grid Improves Freedom from Atrial Fibrillation and Redo Procedures Compared to Circular Mapping Catheter. Journal of Atrial Fibrillation, 13(2).
  2. Abbott report on file. CL1017540
  3. Olson N, Lo M, Zahwe F, Gururaj A, Martel JA, Bernard ML, Tao C and Venkataraman R. The effect of dynamic mapping data on procedure efficiency in radiofrequency ablation of patients with atrial fibrillation. Abstracts from the 26th Annual International Atrial Fibrillation Symposium. Journal of Cardiovascular Electrophysiology. 2021;32:1467-1515.
  4. Abbott. Data on File. Document 90114565.
  5. Goya M, et al. The use of intracardiac echocardiography catheters in endocardial ablation of cardiac arrhythmia: Meta-analysis of efficiency, effectiveness, and safety outcomes. J Cardiovasc Electrophysiol. 2020;31:664–673.
  6. Abbott. Data on File. Document 90569806.
  7. Bourier, F., Gianni, C., Dare, M., Deisenhofer, I., Hessling, G., Reents, T., . . . Al-Ahmad, A. (2017). Fiberoptic contact-force sensing electrophysiological catheters: how precise is the technology? Journal of Cardiovascular Electrophysiology, 28(1), 109-114.
  8. Bourier F, Deisenhofer I, Hessling G, et al. Contact-force sensing electrophysiological catheters: How accurate is the technology? [Abstract PO03-170]. Presentation at HRS 2016, San Francisco, CA, May 4-7, 2016. Heart Rhythm. 2016;13(5 Suppl 1):S318-S319.
  9. Piorkowski, C., Eitel C., Rolf, S., Bode, K., Sommer, P., Gaspar, T., … Hindricks, G.(2011). Steerable versus non-steerable sheath technology in AF ablation: A prospective, randomized study. Circulation, 4(2), 157-65. https://dx.doi.org/10.1161/CIRCEP.110.957761
  10. Lo MY, Sanders P, Sommer P, Kalman JM, Siddiqui UR, Sundaram S, Piorkowski C, Olson N, Madej SM and Gibson DN. Safety and Effectiveness of a Next-Generation Contact Force Catheter. JACC: Clinical Electrophysiology. 2021;0.
  11. Mansour, M. (2014) TOCCASTAR: Preliminary Results of the First Prospective Randomized Study of a Contact Force Sensing Ablation Catheter for the Treatment of Paroxysmal AF. Presented at HRS 2014. San Francisco, California.
  12. Hildick Smith D et al, Left atrial appendage occlusion with the Amplatzer Amulet device: full results of the prospective global observational study; European Heart Journal 2020;41(30):2894-2901.
  13. Amplatzer Amulet LAA Occluder Instructions for Use.

MAT-2211655 v1.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0